ConductScience.org, home

Paper30128811

Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Klausner G and 9 others. Med Oncol, 2018. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. Papers, record 30128811. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30128811

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.
PubMed
Journal
Med Oncol
PubMed
Year
2018
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.22
iCite
Revised in PubMed
2018-12-11
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Klausner GGuillaume
2Blais EEivind
3Jumeau RRaphaël
4Biau JJulian
5de Meric de Bellefon MMailys
6Ozsahin MMahmut
7Zilli TThomas
8Miralbell RRaymond
9Thariat JJuliette
10Troussier IIdrisshttps://orcid.org/0000-0001-9355-0471

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Anus NeoplasmsMajor topic
Carcinoma, Squamous CellMajor topic
Disease ManagementMajor topic
Radiotherapy, Intensity-ModulatedMajor topic
Combined Modality Therapy
Humans
Neoplasm Staging

Source PubMed

Download CSV of topics

References93

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128258896The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma.Int J Radiat Oncol Biol Phys2017https://conductscience.org/library/papers/28258896PubMed
225467588Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).Lancet2015https://conductscience.org/library/papers/25467588PubMed
325950188Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.Cancer Invest2015https://conductscience.org/library/papers/25950188PubMed
43920734Squamous cell carcinoma of the anal canal: treatment by external beam irradiation.Radiother Oncol1985https://conductscience.org/library/papers/3920734PubMed
53568920Epidermoid carcinoma of the anal canal. A series of 276 cases.Dis Colon Rectum1987https://conductscience.org/library/papers/3568920PubMed
68874455
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Lancet1996https://conductscience.org/library/papers/8874455PubMed
723578724Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.Lancet Oncol2013https://conductscience.org/library/papers/23578724PubMed
86326995Carcinoma of the anal canal. A clinical and pathologic study of 188 cases.Cancer1984https://conductscience.org/library/papers/6326995PubMed
927523411[Radiotherapy for anal canal cancers].Cancer Radiother2016https://conductscience.org/library/papers/27523411PubMed
1018430910Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.JAMA2008https://conductscience.org/library/papers/18430910PubMed
1112555997Prognostic factors in anal carcinoma.Pathology2002https://conductscience.org/library/papers/12555997PubMed
1222278906Definitive organ-sparing treatment of anal canal cancer: can we afford to question it?J Clin Oncol2012https://conductscience.org/library/papers/22278906PubMed
1318472366EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.Int J Radiat Oncol Biol Phys2008https://conductscience.org/library/papers/18472366PubMed
1419203845Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.Int J Radiat Oncol Biol Phys2009https://conductscience.org/library/papers/19203845PubMed
1519392867Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.Aliment Pharmacol Ther2009https://conductscience.org/library/papers/19392867PubMed
1616607677Molecular biology of squamous cell carcinoma of the anus.Br J Surg2006https://conductscience.org/library/papers/16607677PubMed
1722285668Setup variations in radiotherapy of anal cancer: advantages of target volume reduction using image-guided radiation treatment.Int J Radiat Oncol Biol Phys2012https://conductscience.org/library/papers/22285668PubMed
1828972796PET imaging in anal canal cancer: a systematic review and meta-analysis.Br J Radiol2017https://conductscience.org/library/papers/28972796PubMed
1926457030Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.World J Gastroenterol2015https://conductscience.org/library/papers/26457030PubMed
2011395235The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.Int J Radiat Oncol Biol Phys2001https://conductscience.org/library/papers/11395235PubMed

See all 93 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
40120019Radiomics to predict tumor response to combination chemoradiotherapy in squamous cell carcinoma of the anal canal: a preliminary investigation.Eur Radiol Exp2025https://conductscience.org/library/papers/40120019PubMed
32842617Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients.J Clin Med2020https://conductscience.org/library/papers/32842617PubMed
31574418Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).Eur J Cancer2019https://conductscience.org/library/papers/31574418PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30128811

GET https://conductscience.org/api/papers/v1/30128811/references?page=2